Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Aquestive Therapeutics

Aquestive Therapeutics
PUBLIC STATUS
201-300 EMPLOYEES
AQST STOCK SYMBOL
3 INVESTMENTS
$3.54 SHARE PRICE (As of Monday Closing)
Description

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.

Formerly Known As
MonoSol Rx
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aquestive Therapeutics’s full profile, request a free trial.

Aquestive Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.96 - $18.49 $88.6M $3.39 -$2.61 112K 25M

Aquestive Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 112,554 139,958
Revenue 53,863 67,430 66,918 51,785
EBITDA (54,460) (50,981) 2,565 432
Net Income (64,180) (61,376) (8,943) (9,602)
Total Assets 50,408 86,851 43,116 39,389
Total Debt 47,434 47,203 45,507 38,650
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aquestive Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Aquestive Therapeutics‘s full profile, request access.

Request full access to PitchBook

Aquestive Therapeutics Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cure Pharmaceutical Angel-Backed Oxnard, CA 00 0000 00000 0000
00000000 Corporate Backed or Acquired Basel, Switzerland 000000 000000000000
0. 00000000-00 000 Corporation Basel, Switzerland 00000 00000 00000000000
000000 000000 0000 Corporation Toronto, Canada 00 0000000000
00000 000000000000 Formerly VC-backed Bridgewater, NJ 0000 00000 000000&0
To view this company’s complete list of competitors, request access »

Aquestive Therapeutics Investments (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 00000000 29-May-2007 0000000000 00000 Other Commercial Products 000 00000
00000000 (0000000 29-May-2007 0000000000 Other Containers and Packaging
RespondTV 26-Jul-2000 Later Stage VC 000.00 Social Content
To view this company’s complete investment and acquisition history, request access »

Aquestive Therapeutics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 26-Jul-2000 00000 00000 00 000.00 Completed
  • 8 buyers
To view this company’s complete exits history, request access »

Aquestive Therapeutics Executive Team (8)

Name Title Board
Seat
Contact
Info
Keith Kendall Chief Executive Officer & Board Member
John Maxwell Chief Financial Officer & Chief Accounting Officer
Daniel Barber Chief Operating Officer & Senior Vice President
Mark Schobel Chief Innovation & Technology Officer
Ken Marshall Executive

2 Former Executives

You’re viewing 5 of 8 executives. Get the full list »

Aquestive Therapeutics Board Members (4)

Name Representing Role Since Contact
Info
00000 00000000 Self Board Member 000 0000
00000 0000000 Aquestive Therapeutics Chief Executive Officer & Board Member 000 0000
00000 000000 Self Board Member 000 0000

1 Former Board Member

You’re viewing 3 of 4 board members. Get the full list »